Clinical trial
90Y-IBRITUMOMAB Tiuxetan and AHCI With HD Chemotherapy and Autologous…
NCT00186589 · Stanford University, Other · Completed
Key facts
| NCT number | NCT00186589 |
|---|---|
| Title | 90Y-IBRITUMOMAB Tiuxetan and AHCI With HD Chemotherapy and Autologous Transplantation for Relapsed or Resistant NHL |
| Official title | 90Y-Ibritumomab Tiuxetan and Autologous Hematopoietic Cell Infusion Followed by High Dose Chemotherapy and Autologous Transplantation for Relapsed or Resistant Non-Hodgkin's Lymphoma |
| Lead sponsor | Stanford University, Other |
| Collaborators | Biogen Industry National Institutes of Health (NIH) NIH |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Lymphoma, Non-Hodgkin, Blood and Marrow Transplant (BMT) |
| Intervention type | Drug |
| Interventions | 90Y Ibritumomab tiuxetan |
| Enrollment | 30 |
| Start date | May 1, 2004 |
| Primary completion | Jul 1, 2007 |
| Completion | Jul 1, 2007 |
| First posted | Sep 16, 2005 |
| Last update posted | Jun 6, 2012 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: